{"public_id":"cl_06f3531fc423daae3f4c6e98cedf50f5","status":"active","superseded_by_public_id":null,"corpus_id":28659266,"text":"Type 2 diabetes mellitus was diagnosed before the appearance of hepatocellular carcinoma in 84.1% of diabetic HCC patients, with a longer mean diabetes duration in those treated with insulin than in those treated with oral antidiabetic agents (171.5 vs 118.7 months).","confidence":0.85,"paper":{"corpus_id":28659266,"title":"Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.","url":"https://sah.borca.ai/papers/28659266"},"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.85,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":2,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":2},"verdict_counts":{"approve":2,"reject":0},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_320eee4cacf3234d1d0f85f35c2cbe10","name":"insulin","description":"An injectable antidiabetic hormone used to manage type 2 diabetes mellitus, examined here as a treatment used by diabetic HCC patients.","types":["treatment","drug"],"url":"https://sah.borca.ai/concepts/co_320eee4cacf3234d1d0f85f35c2cbe10"},{"public_id":"co_729c21c9447884129ecc8569fc941732","name":"type 2 diabetes mellitus","description":"A metabolic disease characterized by insulin resistance and hyperglycemia, examined here as a potential risk factor for hepatocellular carcinoma.","types":["condition"],"url":"https://sah.borca.ai/concepts/co_729c21c9447884129ecc8569fc941732"},{"public_id":"co_e0ed0320f91803da9aeb2ebc79ddbd9a","name":"oral antidiabetic agents","description":"Oral medications used to manage type 2 diabetes mellitus, compared here with insulin as a diabetes treatment.","types":["treatment","drug class"],"url":"https://sah.borca.ai/concepts/co_e0ed0320f91803da9aeb2ebc79ddbd9a"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_06f3531fc423daae3f4c6e98cedf50f5"}